Fjarde Ap-Fonden Fourth Swedish National Pension Fund Position in Abbvie INC (ABBV) Decreased as Share Value Declined

September 14, 2018 - By Andrea Pope

AbbVie Inc. (NYSE:ABBV) LogoInvestors sentiment increased to 0.94 in 2018 Q2. Its up 0.24, from 0.7 in 2018Q1. It is positive, as 55 investors sold ABBV shares while 614 reduced holdings. 107 funds opened positions while 524 raised stakes. 1.00 billion shares or 5.08% less from 1.06 billion shares in 2018Q1 were reported. Regal Limited Liability Co holds 1.52% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 54,055 shares. Albion Fincl Gru Ut owns 5,534 shares or 0.07% of their US portfolio. Welch Gru Ltd Company owns 278,991 shares. Vantage Invest Advsrs Limited Liability Corporation invested 0.02% in AbbVie Inc. (NYSE:ABBV). Broderick Brian C reported 20,605 shares. North Star Investment Corporation has 0.64% invested in AbbVie Inc. (NYSE:ABBV). Guyasuta Investment invested in 0.26% or 24,107 shares. Waters Parkerson & Communications Lc accumulated 3,429 shares or 0.03% of the stock. Lee Danner & Bass Incorporated invested in 0.13% or 14,186 shares. Copeland Cap Lc invested 0.02% in AbbVie Inc. (NYSE:ABBV). Quantitative Systematic Strategies Limited Liability Corp invested 0.04% of its portfolio in AbbVie Inc. (NYSE:ABBV). Jefferies Ltd Liability Corp holds 195,231 shares or 0.1% of its portfolio. Culbertson A N Communication accumulated 2.32% or 84,192 shares. Glenmede Tru Co Na invested 0.64% of its portfolio in AbbVie Inc. (NYSE:ABBV). Amica Mutual Insur reported 0.59% stake.

Since June 15, 2018, it had 2 insider buys, and 2 selling transactions for $6.03 million activity. 17,588 shares valued at $1.75M were sold by RICHMOND TIMOTHY J. on Friday, June 15. RAPP EDWARD J bought $99,909 worth of AbbVie Inc. (NYSE:ABBV) on Wednesday, June 20. The insider TILTON GLENN F bought $496,274.

Fjarde Ap-Fonden Fourth Swedish National Pension Fund decreased its stake in Abbvie Inc (ABBV) by 7.47% based on its latest 2018Q2 regulatory filing with the SEC. Fjarde Ap-Fonden Fourth Swedish National Pension Fund sold 33,734 shares as the company’s stock declined 4.45% while stock markets rallied. The institutional investor held 417,765 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $38.71M, down from 451,499 at the end of the previous reported quarter. Fjarde Ap-Fonden Fourth Swedish National Pension Fund who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $144.93 billion market cap company. The stock decreased 0.64% or $0.62 during the last trading session, reaching $95.71. About 925,214 shares traded. AbbVie Inc. (NYSE:ABBV) has risen 6.26% since September 14, 2017 and is uptrending. It has underperformed by 9.36% the S&P500.

Fjarde Ap-Fonden Fourth Swedish National Pension Fund, which manages about $6.62 billion US Long portfolio, upped its stake in Aes Corp (NYSE:AES) by 252,451 shares to 360,349 shares, valued at $4.83 million in 2018Q2, according to the filing. It also increased its holding in Amphenol Corp New (NYSE:APH) by 39,213 shares in the quarter, for a total of 93,517 shares, and has risen its stake in Nextera Energy Inc (NYSE:NEE).

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on October, 26. They expect $2.01 earnings per share, up 42.55 % or $0.60 from last year’s $1.41 per share. ABBV’s profit will be $3.04 billion for 11.90 P/E if the $2.01 EPS becomes a reality. After $2.00 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 0.50 % EPS growth.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Seekingalpha.com which released: “AbbVie, Inc. (ABBV) Management Presents at Morgan Stanley 16th Annual Global Healthcare Conference (Transcript)” on September 12, 2018, also Seekingalpha.com with their article: “Principia Biopharma readies IPO” published on August 18, 2018, Seekingalpha.com published: “MRD negativity data added to label of AbbVie’s Venclexta” on September 11, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Fool.com and their article: “3 Things You Might Be Overlooking With AbbVie” published on September 14, 2018 as well as Nasdaq.com‘s news article titled: “A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis” with publication date: September 14, 2018.

AbbVie Inc. (NYSE:ABBV) Ratings Coverage

Among 14 analysts covering AbbVie (NYSE:ABBV), 5 have Buy rating, 2 Sell and 7 Hold. Therefore 36% are positive. AbbVie had 21 analyst reports since March 22, 2018 according to SRatingsIntel. The stock has “Neutral” rating by Credit Suisse on Friday, April 27. The stock has “Buy” rating by Argus Research on Monday, June 11. On Wednesday, August 22 the stock rating was maintained by Bank of America with “Buy”. Barclays Capital maintained AbbVie Inc. (NYSE:ABBV) rating on Thursday, April 5. Barclays Capital has “Equal-Weight” rating and $102 target. The rating was downgraded by Credit Suisse to “Underperform” on Wednesday, May 30. The stock has “Buy” rating by Bank of America on Monday, July 30. The rating was maintained by Credit Suisse on Friday, June 22 with “Sell”. PiperJaffray downgraded AbbVie Inc. (NYSE:ABBV) on Friday, June 1 to “Neutral” rating. The firm earned “Buy” rating on Thursday, March 22 by SunTrust. On Friday, March 23 the stock rating was maintained by BMO Capital Markets with “Underperform”.

AbbVie Inc. (NYSE:ABBV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.